Coral laboratories has successfully completed the capacity expansion of its General Pharmaceuticals Formulation unit at its Dehradun plant. The company announced on March 23, 2026, that the expansion project has been completed and commercial operations have commenced at the enhanced facility.

Capacity Expansion Details

The expansion project focused on the General Pharmaceuticals Formulation (Ointment) unit at the Dehradun manufacturing facility. The key parameters of the completed expansion include:

Project Timeline and Implementation

The capacity expansion project was initially announced by the company on October 13, 2025. The successful completion of the project within approximately five months demonstrates the company's execution capabilities in scaling its manufacturing operations.

Commercial Operations Commencement

Coral Laboratories confirmed that the expanded facility has commenced commercial operations, indicating that the enhanced production capacity is now contributing to the company's manufacturing output. The operational commencement marks the successful transition from the expansion phase to active production at the increased capacity levels.

Strategic Manufacturing Enhancement

The completion of this capacity expansion represents a significant enhancement to Coral Laboratories' manufacturing capabilities in the pharmaceutical formulation segment. The expanded ointment production capacity of 360,000 kgs positions the company to meet increased market demand and strengthen its presence in the General Pharmaceuticals Formulation category.

Coral Laboratories Limited announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025, revealing a challenging performance with significant declines in both revenue and profitability. The Board of Directors approved these results during their meeting held on February 13, 2026.

Quarterly Financial Performance

The company's Q3FY26 performance showed substantial year-over-year declines across key financial metrics. Revenue from operations decreased to ₹2156.42 lakhs compared to ₹2298.61 lakhs in Q3FY25, marking a 6.19% decline.

Cost Structure and Operational Metrics

The company's cost structure revealed mixed trends during the quarter. Cost of materials consumed increased significantly to ₹1293.10 lakhs from ₹898.16 lakhs in Q3FY25, representing a 43.98% rise. However, the company benefited from a favorable change in inventories, recording a decrease of ₹500.00 lakhs compared to an increase of ₹32.30 lakhs in the previous year.

Nine-Month Performance Analysis

The nine-month period ended December 31, 2025, showed even more pronounced declines. Revenue from operations dropped 31.60% to ₹5942.04 lakhs from ₹8687.06 lakhs in the corresponding period of the previous year. Net profit for the nine-month period declined 47.70% to ₹1115.74 lakhs compared to ₹2132.86 lakhs in the previous year.

Financial Position and Other Details

The company maintained its paid-up equity share capital at ₹357.26 lakhs with a face value of ₹10 per share throughout the reporting periods. Total comprehensive income for Q3FY26 was ₹76.02 lakhs compared to ₹739.78 lakhs in Q3FY25, reflecting the impact of other comprehensive income adjustments.

Coral Laboratories operates in a single business segment of "Formulations" and does not have any subsidiary, associate, or joint venture companies. The financial results were reviewed by the Audit Committee and approved by the Board of Directors, with statutory auditors S.C. Mehra & Associates LLP conducting a limited review of the results.